Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kevin Grogan

Managing Editor

London, UK

Kevin Grogan has been writing about pharmaceuticals for over twenty years in roles that have included online editor for PharmaTimes. After four years freelancing, which involved writing for all the principal titles in the sector, as well as consultancy work with major pharmaceutical companies, he joined Scrip as Managing Editor, Europe, Commercial in the summer of 2017.

Covering all aspects of the pharma industry, Kevin has interviewed pretty much all the leading figures in the sector, both in the UK and globally. A regular attendee at financial and medical conferences worldwide (and moderating at some), he has also appeared on BBC television and radio, ITV and Channel 4 to discuss events in the pharmaceutical industry.

Fluent in Spanish, he previously worked as a journalist on rock/pop music publications, was chief sub editor at the Catholic weekly newspaper The Universe and also contributed articles to the likes of The Independent and the Manchester Evening News on football.

Advertisement
Set Alert for Articles By Kevin Grogan

Latest From Kevin Grogan

Pharma Q4 Results Preview: J&J, Novartis, Celgene, Biogen & AbbVie

Novartis expected to give Joe Jimenez a good farewell gift; AbbVie says it is not planning major M&A to focus on risankizumab and upadacitinib, but Celgene is on the hunt for deals – will Juno be its next big buy?

Sales & Earnings M & A

Should Celgene Succumb To The Charms Of Juno?

Observers are weighing up whether it makes sense for Celgene to spend in the region of $12bn and plump for the promise of Juno's CAR-T program and whether it would be forced to abandon another promising partner in bluebird.

M & A Commercial

Scrip Company Of The Year Celgene In Rude Health Despite Hiccups

Celgene, which continues to plough back a very high proportion of its revenues into R&D, remains the preferred partner of choice for biotechs who hope to bring the next wave of innovative products to the market, Kevin Loth, VP of corporate affairs and policy in Europe tells Scrip.

Commercial Business Strategies

All Systems Go as Roche MS Drug Ocrevus Secures EU Okay At Last

Now that the European Commission has finally given the go-ahead to Ocrevus, regarded by multiple sclerosis specialists as a game changer especially for the primary progressive form of the disease, observers will be watching to see what pricing strategy Roche adopts.

Approvals Neurology

Ferring Forges Fertility Pact With Chinese Academy of Sciences

The Swiss firm's chief scientific officer tells Scrip that working with world-renowned researchers in Beijing can only help Ferring achieve its goal of becoming the number one reproductive medicines company.

Deals Companies

Deal Watch: As J.P. Morgan Waits For New Deals, Sanofi Takes Care Of Old Business

Alder ended a patent dispute with Teva with a deal that will enable it to take its Phase III migraine candidate forward, while Sanofi restructures pair of partnerships with Alnylam and Regeneron heading into the J.P. Morgan Healthcare conference – where despite a flow of mid-stage deals, stakeholders are hoping US tax reform means bigger deals to come.

Deals Business Strategies
See All
Advertisement
UsernamePublicRestriction

Register